M E Autenrieth1, T Horn2, F Kurtz2, K Nguyen2, A Morgenstern3, F Bruchertseifer3, M Schwaiger4, M Blechert4, C Seidl4, R Senekowitsch-Schmidtke4, J E Gschwend2, K Scheidhauer4. 1. Klinik und Poliklinik für Urologie, Klinikum rechts der Isar, TU München, München, Deutschland. michael.autenrieth@tum.de. 2. Klinik und Poliklinik für Urologie, Klinikum rechts der Isar, TU München, München, Deutschland. 3. Institut für Transurane der Europäischen Kommission, Karlsruhe, Deutschland. 4. Klinik und Poliklinik für Nuklearmedizin, Klinikum rechts der Isar, TU München, München, Deutschland.
Abstract
BACKGROUND: In failure to respond to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ (CIS) of the urinary bladder, radical cystectomy remains the mainstay after BCG failure. OBJECTIVES: The aim of this pilot study was to evaluate tolerability and safety of the α‑emitter radioimmunoconjugate instillation in patients after BCG failure. MATERIALS AND METHODS: Nine patients were included. After emptying the bladder via a transurethral catheter, Bi-213-anti-EGFR-mAb was instilled. Treatment was terminated by emptying of the radioimmunoconjugate from the bladder 120 min after instillation. Efficacy was evaluated via endoscopy and histology 6 weeks after instillation. RESULTS: All patients showed excellent toleration of the treatment without any side effects. Treatment resulted in complete eradication of tumor cells in 3 patients and persistent tumor detection in the other 6 patients. CONCLUSIONS: Intravesical instillation of Bi-213-anti-EGFR-mAb is a promising therapeutic option for treatment of in situ bladder cancer after BCG failure for patients who wish to preserve the bladder.
BACKGROUND: In failure to respond to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ (CIS) of the urinary bladder, radical cystectomy remains the mainstay after BCG failure. OBJECTIVES: The aim of this pilot study was to evaluate tolerability and safety of the α‑emitter radioimmunoconjugate instillation in patients after BCG failure. MATERIALS AND METHODS: Nine patients were included. After emptying the bladder via a transurethral catheter, Bi-213-anti-EGFR-mAb was instilled. Treatment was terminated by emptying of the radioimmunoconjugate from the bladder 120 min after instillation. Efficacy was evaluated via endoscopy and histology 6 weeks after instillation. RESULTS: All patients showed excellent toleration of the treatment without any side effects. Treatment resulted in complete eradication of tumor cells in 3 patients and persistent tumor detection in the other 6 patients. CONCLUSIONS: Intravesical instillation of Bi-213-anti-EGFR-mAb is a promising therapeutic option for treatment of in situ bladder cancer after BCG failure for patients who wish to preserve the bladder.
Authors: Julia Fazel; Silvia Rötzer; Christof Seidl; Benedikt Feuerecker; Michael Autenrieth; Gregor Weirich; Frank Bruchertseifer; Alfred Morgenstern; Reingard Senekowitsch-Schmidtke Journal: Cancer Biol Ther Date: 2015-07-15 Impact factor: 4.742
Authors: Eero Kaasinen; Hans Wijkström; Per Uno Malmström; Sverker Hellsten; Milos Duchek; Oddvar Mestad; Erkki Rintala Journal: Eur Urol Date: 2003-06 Impact factor: 20.096
Authors: Alfred Morgenstern; Christos Apostolidis; Clemens Kratochwil; Mike Sathekge; Leszek Krolicki; Frank Bruchertseifer Journal: Curr Radiopharm Date: 2018
Authors: Narges K Tafreshi; Michael L Doligalski; Christopher J Tichacek; Darpan N Pandya; Mikalai M Budzevich; Ghassan El-Haddad; Nikhil I Khushalani; Eduardo G Moros; Mark L McLaughlin; Thaddeus J Wadas; David L Morse Journal: Molecules Date: 2019-11-26 Impact factor: 4.411